PressCenter.com  - Free Press Release Distribution Platform
No Result
View All Result
Wednesday, February 1, 2023
  • Login
  • Register
  • Home
  • Categories
    • Art & Culture
    • Business & Entrepreneurship
    • Economy & Finances
    • Education & Parenting
    • Energy & Environment
    • Government & Politics
    • Health & Beauty
    • Internet & IT
    • Lifestyle & Fashion
    • Media & Social Networks
    • Society & Welfare
    • Sport & Leisure
    • Technology & Science
    • Traffic & Safety
    • Work & Career
  • Countries
    • Belgium
    • Europe
    • France
    • Germany
    • International
    • Luxembourg
    • Netherlands
    • Others
    • Russia
    • UK
  • Service Portal
    • Press Release Distribution
    • My Press Releases
    • Add Press Release – FREE
    • Service Packs
ADD PRESS RELEASE
PressCenter.com  - Free Press Release Distribution Platform
  • Home
  • Categories
    • Art & Culture
    • Business & Entrepreneurship
    • Economy & Finances
    • Education & Parenting
    • Energy & Environment
    • Government & Politics
    • Health & Beauty
    • Internet & IT
    • Lifestyle & Fashion
    • Media & Social Networks
    • Society & Welfare
    • Sport & Leisure
    • Technology & Science
    • Traffic & Safety
    • Work & Career
  • Countries
    • Belgium
    • Europe
    • France
    • Germany
    • International
    • Luxembourg
    • Netherlands
    • Others
    • Russia
    • UK
  • Service Portal
    • Press Release Distribution
    • My Press Releases
    • Add Press Release – FREE
    • Service Packs
No Result
View All Result
PressCenter.com  - Free Press Release Distribution Platform
No Result
View All Result
Home Sources Business & Entrepreneurs

New trial results support treatment with Inspra (eplerenone) within first 24 hours of symptoms, in addition to standard therapy, in patients with acute STEMI without heart failure.

by PressCenter.com
April 5, 2013
in Business & Entrepreneurs, Categories, Health & Beauty, Sources
0
1.2k
SHARES
2k
VIEWS
Share on FacebookShare on TwitterLinkedIn
ADVERTISEMENT

Pfizer Inc. (NYSE: PFE) today announced results from the REMINDER trial showing statistically significant risk reductions in the primary composite efficacy endpoint. The composite endpoint was defined as the time to first event of cardiovascular (CV) mortality, re-hospitalization or extended initial hospital stay due to diagnosis of heart failure (HF), sustained ventricular tachycardia or fibrillation, ejection fraction (EF) ≤40% after 1 month, or an elevation of BNP/ NT-proBNP after 1 month.

The results were presented for the first time during the Late Breaker Clinical Trial session at the 62nd Annual Scientific Session of the American College of Cardiology in San Francisco today.

The REMINDER trial was a randomized, double-blind trial, involving 1,012 patients with acute ST-segment elevation myocardial infarction (STEMI) without a history of HF or EF <40% and without signs of HF. Patients received, preferably before myocardial reperfusion, either eplerenone (25-50 mg OD) or placebo in addition to standard therapy. Treatment was initiated within the first 24 hours of symptom onset (preferably within first 12h). The REMINDER trial demonstrated a statistically significant 42.9% relative risk reduction in the primary endpoint with p < 0.0001 (95% confidence interval [CI] 0.439, 0.742) in patients with acute STEMI when eplerenone was initiated within the first 24 hours of onset of symptoms. Overall, the adverse events reported in the REMINDER trial were consistent with those already known for eplerenone, primarily hyperkalemia. Eplerenone is not approved for use in the patient population studied in the REMINDER trial in any market. The improvement in outcome was mainly driven by a significant reduction of the BNP / NT-proBNP biomarker component at 1 month. BNP/NT-proBNP has been shown to be an important marker for short- and long-term prognosis in patients with myocardial infarction in the presence or absence of preserved ejection fraction. An elevation of BNP / NT-proBNP after 1 month was observed less frequently in the eplerenone group 81(16.0%) than in the placebo group 131(25.9%) (adjusted HR, 0.584; 95% CI 0.441-0.773; p=0.0002). Over the course of the study, the incidence of hyperkalemia (elevated potassium defined as serum potassium levels exceeding 5.5 mEq/L) occurred in 5.6% vs. 3.2% (p=0.09) in the eplerenone and placebo groups, respectively. Hypokalemia (serum potassium level below 3.5 mEq/L) occurred more frequently in the placebo group with 1.4% vs. 5.5% (p=0.0002) in the eplerenone and placebo groups, respectively. The rates of other adverse events were similar in both groups. Commenting on the findings, the chair of the REMINDER Steering Committee Professor Gilles Montalescot, Institute of Cardiology, Centre Hospitalier Pitié-Salpêtriėre, Paris, France said: “Eplerenone improved the outcome of patients presenting with acute STEMI and without concomitant heart failure. This benefit was obtained in a low-risk population that was well treated, without serious adverse drug effect. Adding eplerenone to standard therapy as early as within the first 24 hours of symptoms reduced heart failure-related morbidity.”

About the REMINDER trial

The REMINDER trial was a randomized, double-blind trial, involving 1012 patients with acute STEMI without a history of HF or EF <40% and without signs of HF. The REMINDER trial was conducted in 11 countries: Canada, Czech Republic, France, Germany, Greece, Hungary, Netherlands, Poland, Slovakia, Spain, UK. The primary objective of the REMINDER trial was to assess the efficacy of Inspra 25 -50 mg once daily, compared to placebo, in the early treatment of acute ST-segment elevation myocardial infarction (STEMI) within 24 hours (preferably within the first 12h). The mean follow-up time was 10.5 months. The study was funded by Pfizer.

About INSPRA®

INSPRA® (eplerenone) is a steroid nucleus-based mineralcorticoid receptor (MR) antagonist with a higher degree of selectivity than spironolactone.

Important Prescribing Information

In the United States, Inspra® (eplerenone) is indicated to improve survival of stable patients with left ventricular (LV) systolic dysfunction (ejection fraction less than or equal to 40%) and clinical evidence of congestive heart failure (CHF) after an acute myocardial infarction (MI). Eplerenone is also indicated for the treatment of hypertension. Eplerenone may be used alone or in combination with other antihypertensive agents.

Eplerenone is contraindicated in all patients with serum potassium greater than 5.5 mEq/L at initiation, creatinine clearance less than or equal to 30 mL/min, or concomitant administration of strong CYP3A4 inhibitors. Eplerenone is also contraindicated for the treatment of hypertension in patients with type 2 diabetes with microalbuminuria, serum creatinine greater than 2.0 mg/dL in males or greater than 1.8 mg/dL in females, creatinine clearance less than 50 mL/min, or concomitant administration of potassium supplements or potassium sparing diuretics.

Serum potassium should be measured before initiating eplerenone therapy, within the first week, and at one month after the start of treatment or dose adjustment. Serum potassium should be assessed periodically thereafter, especially in patients at risk for the development of hyperkalemia such as elderly patients with renal insufficiency and patients with type 2 diabetes and microalbuminuria.

Most common adverse reactions (greater than 2% and more frequent than with placebo) in patients with CHF Post-MI: hyperkalemia and increased creatinine. Most common adverse reactions (greater than or equal to 2% and more frequent than with placebo) in hypertensive patients: dizziness, diarrhea, coughing, fatigue and flu-like symptoms.

ADVERTISEMENT

In the European Union, eplerenone is indicated, in addition to standard optimal therapy, to reduce the risk of cardiovascular mortality and morbidity in adult patients with NYHA class II (chronic) heart failure and left ventricular systolic dysfunction (LVEF ≤30%). Eplerenone is also indicated to reduce the risk of cardiovascular mortality and morbidity in stable patients with left ventricular dysfunction (LVEF ≤40%) and clinical evidence of heart failure after recent myocardial infarction.

In Japan, eplerenone is approved for the treatment of hypertension.

For additional product information in the US, visit
http://media.pfizer.com/files/products/uspi_inspra.pdf

UK prescribing information is available at
http://www.medicines.org.uk/EMC/medicine/16746/SPC/Inspra+25mg+%26+50+mg+film-coated+tablets/

Other countries should refer to local prescribing information.

Tags: heart deseasemedicationmortalityprescription drugs
ADVERTISEMENT
ADVERTISEMENT
CX Forums Announces Spring Experience Summits
Business & Entrepreneurship

CX Forums Announces Spring Experience Summits

by dnldhd9
January 31, 2023
0

(1888PressRelease) - CX Forums announces events for customer experience professionals in St. Pete, Atlanta and Chicago.

Read more
Hamptons Greece Brings New York Lifestyle to Greece.

Hamptons Greece Brings New York Lifestyle to Greece.

January 30, 2023
Perenio presents a line of new smart products at ISE 2023 in Barcelona

Perenio presents a line of new smart products at ISE 2023 in Barcelona

January 27, 2023
Air Ambulance Market will Predicted to Grow at a 5% CAGR

Air Ambulance Market will Predicted to Grow at a 5% CAGR

January 27, 2023
Thailand ready to place youth basketball on the international map

Thailand ready to place youth basketball on the international map

January 28, 2023
PressCenter.com  – Free Press Release Distribution Platform

PressCenter.com is state-of-the-art Press Release Distribution Platform. PressCenter.com send and track your Press Release using our industry-leading global Media Contacts Database of a million contacts. Your Press Release will reach business news editors and journalists, in targeted sectors and territories or worldwide.

ArabicChinese (Simplified)DutchEnglishFrenchGermanItalianPortugueseRussianSpanish

Policies

  • Terms & Conditions
  • Copyrights
  • Cookies
  • Disclaimer
  • Privacy Policy

Services

  • Home
  • Press Release Distribution
  • Add Press Release – FREE
  • Guidelines
  • Advertisement
  • About Us
  • Contact Our Team

Press Releases by E-Mail

To stay on top of the ever-changing world of business, subscribe now to our newsletters.

*We hate spam as you do.

Categories

© 1998-2023 PressCenter.com - Latest Business News and Press Releases

No Result
View All Result
  • Home
  • Press Release Distribution
  • Add Press Release – FREE
  • Advertisement
  • Contact Our Team
  • Guidelines
  • About Us

© 1998-2023 PressCenter.com - Latest Business News and Press Releases

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In